Kashyap A, Dai J, Ni X
Cancers (Basel). 2025; 17(4).
PMID: 40002165
PMC: 11853177.
DOI: 10.3390/cancers17040568.
Bordeaux Z, Reddy S, Lee K, Lu W, Choi J, Miller M
Int J Mol Sci. 2023; 24(9).
PMID: 37175780
PMC: 10179468.
DOI: 10.3390/ijms24098075.
Guo K, Wang L, Zhong Y, Gao S, Jing R, Ye J
Ann Transl Med. 2022; 10(20):1104.
PMID: 36388783
PMC: 9652544.
DOI: 10.21037/atm-22-4423.
Patel A, Rasheed A, Reilly I, Pareek Z, Hansen M, Haque Z
Pharmaceuticals (Basel). 2022; 15(11).
PMID: 36355554
PMC: 9698530.
DOI: 10.3390/ph15111380.
Delgado-Tiburcio E, Cadena-Iniguez J, Santiago-Osorio E, Ruiz-Posadas L, Castillo-Juarez I, Aguiniga-Sanchez I
Pharmaceuticals (Basel). 2022; 15(11).
PMID: 36355498
PMC: 9696414.
DOI: 10.3390/ph15111325.
Safety and Danger Considerations of Novel Treatments for Atopic Dermatitis in Context of Primary Cutaneous Lymphomas.
Kolkowski K, Trzeciak M, Sokolowska-Wojdylo M
Int J Mol Sci. 2021; 22(24).
PMID: 34948183
PMC: 8703592.
DOI: 10.3390/ijms222413388.
Cutaneous T cell lymphoma.
Dummer R, Vermeer M, Scarisbrick J, Kim Y, Stonesifer C, Tensen C
Nat Rev Dis Primers. 2021; 7(1):61.
PMID: 34446710
DOI: 10.1038/s41572-021-00296-9.
Potent Anticancer Effects of Epidithiodiketopiperazine NT1721 in Cutaneous T Cell Lymphoma.
Lin M, Kowolik C, Xie J, Yadav S, Overman L, Horne D
Cancers (Basel). 2021; 13(13).
PMID: 34282785
PMC: 8268131.
DOI: 10.3390/cancers13133367.
Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma.
Garcia-Colmenero L, Gonzalez J, Sandoval J, Guillen Y, Diaz-Lagares A, Andrades E
Cells. 2020; 9(12).
PMID: 33333886
PMC: 7765332.
DOI: 10.3390/cells9122692.
Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in Sézary cells.
Brouwer I, Out-Luiting J, Vermeer M, Tensen C
Biochem Biophys Rep. 2020; 24:100832.
PMID: 33102814
PMC: 7569298.
DOI: 10.1016/j.bbrep.2020.100832.
Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy.
Bose S, Banerjee S, Mondal A, Chakraborty U, Pumarol J, Croley C
Cells. 2020; 9(6).
PMID: 32545187
PMC: 7348822.
DOI: 10.3390/cells9061451.
Targeting STAT-3 signaling pathway in cancer for development of novel drugs: Advancements and challenges.
Arshad S, Naveed M, Ullia M, Javed K, Butt A, Khawar M
Genet Mol Biol. 2020; 43(1):e20180160.
PMID: 32167126
PMC: 7198026.
DOI: 10.1590/1678-4685-GMB-2018-0160.
Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers.
Brachet-Botineau M, Polomski M, Neubauer H, Juen L, Hedou D, Viaud-Massuard M
Cancers (Basel). 2020; 12(1).
PMID: 31963765
PMC: 7016966.
DOI: 10.3390/cancers12010240.
STAT3 Dysregulation in Mature T and NK Cell Lymphomas.
Seffens A, Herrera A, Tegla C, Buus T, Hymes K, Odum N
Cancers (Basel). 2019; 11(11).
PMID: 31684088
PMC: 6896161.
DOI: 10.3390/cancers11111711.
miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.
Xia L, Wu L, Xia H, Bao J, Li Q, Chen X
Cell Cycle. 2019; 18(14):1635-1645.
PMID: 31213131
PMC: 6619951.
DOI: 10.1080/15384101.2019.1629789.
New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.
Fujii K
Front Oncol. 2018; 8:198.
PMID: 29915722
PMC: 5994426.
DOI: 10.3389/fonc.2018.00198.
ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways.
Ni X, Zhang X, Hu C, Langridge T, Tarapore R, Allen J
Oncotarget. 2017; 8(37):61761-61776.
PMID: 28977902
PMC: 5617462.
DOI: 10.18632/oncotarget.18688.
Cell-based phenotypic screening of mast cell degranulation unveils kinetic perturbations of agents targeting phosphorylation.
Qin S, Wang X, Wu H, Xiao P, Cheng H, Zhang X
Sci Rep. 2016; 6:31320.
PMID: 27502076
PMC: 4977535.
DOI: 10.1038/srep31320.
Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.
Willerslev-Olsen A, Krejsgaard T, Lindahl L, Litvinov I, Fredholm S, Petersen D
Blood. 2016; 127(10):1287-96.
PMID: 26738536
PMC: 4786838.
DOI: 10.1182/blood-2015-08-662353.
EPHA4 is overexpressed but not functionally active in Sézary syndrome.
Hameetman L, van der Fits L, Zoutman W, Out-Luiting J, Siegal G, de Esch I
Oncotarget. 2015; 6(31):31868-76.
PMID: 26376612
PMC: 4741646.
DOI: 10.18632/oncotarget.5573.